Study of Avutometinib (VS-6766) +Defactinib With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer
← catalyst calendarNCT05669482 · readout in 12 d
Sponsored by Verastem, Inc. (industry) · VSTM — their whole pipeline →.
Phase
Phase 1/2
Status
Active, not recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
40estimated
Sites
12
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-03-22 | actual | When the study began enrolling |
| Primary completion | 2026-08-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-08-31 | estimated | The whole study's end, after follow-up |
| First posted | 2022-12-30 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-09-02 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- KRAS Activating Mutation
- Metastatic Cancer
- Pancreas Cancer
- Neoplasms Pancreatic
- Malignant Neoplasm of Pancreas
Intervention
- Drug: avutometinib (VS-6766) and defactinib in combination with gemcitabine and nab-paclitaxel — also filed as Gemzar, Abraxane
Primary outcomes
what the primary-completion date above is the date OFPart A: To determine RP2D for avutometinib (VS-6766) and defactinib in combination gemcitabine and nab-paclitaxel
measured 28 days
To determine the efficacy of the RP2D identified in Part A
measured 6 months
Permalink · VSTM's whole pipeline · Catalyst calendar · Every registered study · What changed